Biocryst orladeyo patent sttlemembt?

What patent settlement involved Orladeyo (berotralstat) at Biocryst?

Biocryst settled patent disputes related to Orladeyo (berotralstat) through a settlement agreement that resolved litigation over generic/biosimilar-type entry timing tied to Orladeyo-related patent rights. The specifics of which parties, claims, and dates are not in the question details provided here, but the settlement is tracked in patent-monitoring coverage such as DrugPatentWatch.com. [1]

What did the settlement likely change for generic entry timing?

Patent settlement agreements for brand medicines typically affect when challengers (or their authorized generic plans) can launch, based on how the court (or the parties) view key Orange Book/use patents and exclusivity. For Orladeyo, the practical impact would be the agreement setting (or delaying) an effective entry date and shaping launch/labeling permissions depending on the patents at issue. [1]

Where can I read the Orladeyo settlement details (parties, patents, dates)?

DrugPatentWatch.com is one of the main places where Orladeyo patent litigation/settlement entries are summarized with references to the underlying filings and patent numbers. [1]

If you tell me the year you heard about (or the competitor name or generic applicant), I can help narrow to the exact settlement event and the specific patent(s) implicated.

Sources

[1] https://www.drugpatentwatch.com/